newsfilter
← Latest News
GlobeNewswire·

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AMLMIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the